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Purpose: Evaluation of the neuroprotective effect of weekly glatiramer acetate (GA) on retinal 
structure and function in diabetic patients who underwent panretinal photocoagulation (PRP).
Patients and methods: Patients with severe nonproliferative or early proliferative diabetic 
retinopathy and no previous laser treatment were randomly divided into two groups: (1) those 
who received four GA treatments and (2) those who received placebo treatment. The sub-
cutaneous injections were administered 1 week prior to laser and weekly in the subsequent 
three sessions of PRP in both groups. All patients underwent a full ophthalmic examination 
(best-corrected logMAR visual acuity, slit lamp examination, applanation tonometry, fundus 
biomicroscopy and indirect fundus examination); functional examination (standard automated 
perimetry, electroretinography and frequency-doubling technology C-20 visual field) and ana-
tomic examination (color photography, optical coherence tomography (OCT) and Heidelberg 
retinal tomography). The examinations were performed before the photocoagulation and repeated 
1,3,6, and 12 months after treatment (in a double-masked manner). To compare the two groups, 
generalized estimating equation models were performed to account for the dependence between 
eyes of the same patient.
Results: Thirteen patients (23 eyes) were included in the study group and 13 patients (24 eyes) 
were included in the control group. OCT showed a statistically significant difference in retinal 
nerve fiber layer (RNFL) thickness in the inferior peripapillary region and average thickness with 
thinner measurements in the control group at 1-year post-PRP. Functional analysis demonstrated 
a difference between groups, but it did not reach statistical significance.
Conclusion: The results of this study suggest that weekly GA treatment has a potential neuro-
protective effect on the RNFL following photocoagulation for diabetic retinopathy.
Keywords: diabetic retinopathy, panretinal photocoagulation, glatiramer acetate, 
neuroprotection 
Introduction
Diabetic retinopathy is a leading cause of severe loss of visual acuity despite an increased 
understanding of this disease and the identification of successful treatments.1 The Dia-
betic Retinopathy Study showed the benefits of panretinal photocoagulation (PRP) in 
reducing the risk of severe visual loss by .50% in eyes with high-risk characteristics.2 
The Early Treatment Diabetic Retinopathy Study (ETDRS) confirmed that PRP should 
also be performed in eyes with severe nonproliferative and non-high-risk proliferative 
diabetic retinopathy.3,4 Furthermore, ETDRS5 defined the indications of laser treatment 
in clinically significant macular edema. However, retinal photocoagulation may lead 
to complications and retinal damage. After primary laser injury, the local lesions may 
spread and lead to an increased morphological and functional damage.6–8Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Therefore, we hypothesized that combining laser therapy 
with neuroprotection may improve the outcome of this inter-
vention: neuroprotection aims to prevent the spread of dam-
age resulting from mechanical or biochemical damage.9–13 
The neuroprotective action of weekly glatiramer acetate 
(GA) has been demonstrated in models of neuronal damage 
caused by elevated intraocular pressure and intraocular glu-
tamate toxicity11–14 as well as in chronic neurodegenerative 
conditions such as an animal model of Alzheimer’s disease.15 
This study was conducted to evaluate the outcome of retinal 
anatomy and function in diabetic patients following panreti-
nal photocoagulation, using immune-based neuroprotection 
therapy with weekly administered GA.
Material and methods
In this randomized, controlled clinical trial, we enroled dia-
betic insulin-dependent and noninsulin-dependent patients 
with very severe nonproliferative or early proliferative 
  retinopathy from the Retina Sector of the Federal University 
of São Paulo (UNIFESP) between July 2006 and July 2007. 
The protocol was approved by the Research Ethics Com-
mittee of the Federal University of São Paulo. Informed 
consent was obtained from all participants in accordance 
with the tenets of the 1989 Declaration of Helsinki. Patients, 
  ophthalmologists, technical staff and statisticians participated 
in a masked fashion. The study was conducted using scientific 
methodology based on the Revised CONSORT16 statement 
for randomized trials. Clinical trial identifier (http://www.
ClinicalTrials.gov): NCT00677664.
Patient enrolment and baseline 
evaluation
Patients were included if they had: type 1 or 2 diabetes, been 
recommended for panretinal photocoagulation; vision acuity 
of 20/100 or better; spherical equivalent of ± 6.00 spherical 
diopters. Exclusion criteria related to the eye were:   previous 
retinal photocoagulation or cryopexy of any kind; dense 
cataract or vitreous opacity; retinal disease other than diabetic 
retinopathy; ocular hypertension or glaucoma (IOP higher 
than 21 mmHg and/or cup disk ratio equal to or higher than 
0.8) or other optic nerve diseases; and ocular surgery within 
the last 6 months, including laser treatment. Systemic exclu-
sion criteria were: known immunological condition/disease; 
active infection within 30 days prior to enrolment (eg, urinary 
tract infection, upper/lower respiratory tract infection, skin 
infection, arthritis); use of interferon or immunosuppres-
sive, cytotoxic or corticosteroid chemotherapy or lymphoid 
irradiation within 1 year prior to study entry; serious disease 
in the past or an unstable disease such as cancer, pulmonary, 
hepatic, renal, cardiovascular or metabolic diseases; being 
a volunteer who participated in another clinical trial within 
the past 90 days or took an experimental drug within a 
time scale of 5 × t1/2 of the experimental drug; and unstable 
  psychiatric illness.
All patients were subjected to a series of tests. A full 
ophthalmic examination included best-corrected logarithm 
of minimal angle of resolution (logMAR) visual acuity 
(BCVA) as measured with ETDRS charts, applanation 
tonometry, undilated and dilated slit-lamp biomicroscopic 
examination, and indirect fundus examination. A functional 
examination included Humphrey 30-2 SITA STANDARD 
visual field (Humphrey Field Analyzer, II-750; Carl Zeiss 
Meditec,   Dublin, CA), electroretinography full-field (ERG, 
UTAS E-3000; LKC Technologies Inc, Gaithersburg, MD) 
according to the standard protocol recommended by the 
International Society for Clinical Electrophysiology of 
Vision (ISCEV) and frequency-doubling technology C-20 
visual field (FDT Matrix; Carl Zeiss Meditec). A morpho-
logical examination included: colour fundus photography 
and fluorescein angiography (FA), using a Heidelberg 
retina angiograph, (Heidelberg Engineering, Dossenheim, 
Germany) in cases of clinically significant macular edema; 
these examinations were done in order to guide the focal laser 
treatment. Optical coherence tomography (Stratus OCT3; 
Carl Zeiss Meditech) was performed to measure the retinal 
nerve fiber layer (RNFL) thickness around the optic disk 
and macular area, and Heidelberg retinal tomography (HRT, 
Heidelberg Instruments GmbH, Heidelberg, Germany) was 
performed to measure the optic disk rim area as well as the 
cup disk and rim area.
Treatment assignment
Patients were divided in two groups using a computer-
  generated random table. Numbered opaque envelopes 
contained the type of intervention: GA (GA group) or 
placebo (control group). All data from patients’ examina-
tions were analyzed within the group to which they were 
originally assigned. All patients were treated with laser 
  photocoagulation consisting of full-scatter PRP treatment 
performed during three sessions (at weeks 1, 2, and 3) 
  according to the ETDRS guidelines. Four to six hundred 
250-µm spots were performed per PRP episode at the discre-
tion of the same treating investigator (S Mitne); these spots 
were sequentially performed in each eye on the same day. 
Macular (focal or grid) laser photocoagulation guided by 
FA was also performed in cases with clinically significant Clinical Ophthalmology 2011:5
Table 1 Demographic data and baseline characteristics of patients treated with glatiramer acetate (gA group) and placebo 
(control group)
GA group Control group Mean difference (CI 95%)
Age (years), mean (sD) 54.4 (7.9) 54.9 (11.8) 0.54 (−7.56; 8.64)
gender, n (%)
  Male 5 (38.5%) 8 (61.5%)
  Female 8 (61.5%) 5 (38.5%) 23.1% (−14.3; 60.5)
race, n (%)
  Asian 1 (7.7%) 0 (0%)
  White 9 (69.2%) 11 (84.6%)
  Black 3 (23.1%) 2 (15.4%) −7.7% (−37.8; 22.5)
T_DM (years), mean (sD) 14.8 (6.8) 13.1 (4.3) −1.69 (−6.29; 2.91)
PDr n (%) 10 (76.9%) 8 (61.5%) −15.4% (−50.4; 19.6)
insulin n (%) 3 (23.1%) 8 (61.5%) 38.5% (3.5; 73.4)
gli_i, median (iQr) 172.5 (155.0–220.0) 195.0 (150.0–232.0) 22.5a
gli_6M, median (iQr) 183.5 (160.5–263.0) 150.0 (133.0–160.0) −33.5a
Note: aMedian difference.
Abbreviations: GA group, treated with glatiramer acetate; SD, standard deviation; CI, confidence interval; IQR, interquartile range; T_DM, duration of diabetes; PDR, 
proliferative diabetic retinopathy; gli_i, baseline fasting blood glucose; gli_6M, 6-month fasting blood glucose.
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macular edema at the first laser treatment session (week 1) 
and was repeated after 3 months in cases of persistent macular 
edema. The GA group received injections containing 20 mg 
of glatiramer acetate (also known as Cop-1, Copolymer-1, 
Copaxone™; Teva Pharmaceutical Industries Ltd, Kfar-Saba, 
Israel). The control group received just the vehicle:   mannitol 
injections. All injections of either GA or the vehicle only 
were done subcutaneously 1 week prior to the first PRP 
session and then weekly immediately before the three sub-
sequent PRP sessions.
Follow-up examinations  
and outcome measures
Patients were followed up at 1, 3, 6, and 12 months after the 
completion of the treatment procedures. At these visits, they 
underwent a complete ophthalmic examination including the 
same procedures that were performed at baseline.
Statistical analysis
The sample size calculation was based on previously 
  published data17 in which patients who did not undergo laser 
treatment presented a mean RNFL thickness of 135.8 µm 
in the inferior region and a standard deviation of 29.8 µm. 
Assuming a control group loss of 20% after laser treatment 
vs 1% for the GA group, a sample size of 15 patients per 
group would be necessary to reach a power of 80% and a 
significance level of 5%.
Upon baseline evaluation, the chi-square or Fisher´s exact 
test was used for categorical variables (sex, race, retinopathy 
grade) and Student’s t-test or the Mann–Whitney test was 
used for numeric variables (age, duration of diabetes and 
glycemia). To compare both groups regarding   anatomical 
and functional examinations generalized estimating 
  equation (GEE)18,19 models were performed to account for 
the   dependence between eyes of the same patient. SPSS 
(v 17.0 for Windows; SPSS, Inc, Chicago, IL) was used for 
statistical analysis.
Results
Forty-seven eyes from 26 diabetic patients with very 
severe nonproliferative or proliferative retinopathy were 
included in this study. All patients were treated with 
PRP. Thirteen patients (23 eyes) were included in the GA 
group and   thirteen patients (24 eyes) were included in 
the control group. All patients with clinically significant 
macular edema were treated with macular laser: 15 eyes 
in the GA group and 18 eyes in the control group, with 
no statistically   significant   difference between groups 
(P = 0.32, chi-squared test adjusted for inter-eye depen-
dency). Demographic data and baseline characteristics are 
summarized in Table 1.
Figure 1 shows the participants throughout each stage 
of the study. After enrolment, one patient was excluded 
due to diabetic optic neuropathy. In the allocation phase 
(prior to the treatment), one eye from the GA group and 
two eyes from the control group showed vitreous hemor-
rhage; therefore, laser treatment could not be completed. 
One patient (one eye) from the control group abandoned 
the study before completing the treatment. Another patient 
(one eye) from the control group was dropped from the 
follow-up due to an orthopedic disease 3 months after treat-
ment. During   analysis, all exclusions were performed with Clinical Ophthalmology 2011:5
Assessed for eligibility
(n = 30 patients, 53 eyes)
Excluded
(n = 1 patient, 2 eyes)
Diabetic neuropathy
Lost to follow-up (n = 0)
Lost to follow-up
(n = 1 patient, 1 eye)
Orthopedic disease 3
months after treatment
Analyzed
(n = 13 patients, 23 eyes)
Analyzed
(n = 13 patients, 24 eyes)
1 eye partial follow-up
Allocated to GA group
(n = 14 patients, 24 eyes)
Received allocated 
intervention
(n = 13 patients, 23 eyes)
Did not receive allocated
intervention
(n = 1 patient, 1 eye 
with VH)
Allocated to group B
(n = 15 patients, 27 eyes)
Received allocated 
intervention
(n = 13 patients, 24 eyes)
Did not receive allocated
intervention
(n = 2 patients, 2 eyes with VH,
and 1 did not return)
Enrolment
Randomized
Allocation
Follow-up
Analysis
Figure  1 Diagram  showing  the  flow  of  participants  through  each  stage  of  the 
randomized trial.
Abbreviation: Vh, vitreous hemorrhage.
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the   investigators still masked for anatomical and functional 
evaluation. Partial data for three patients in each group were 
excluded from the main outcome analysis due to vitreous 
hemorrhage (three eyes in the GA group), partial retinal 
detachment (two eyes in the control group), submacular 
hemorrhage (one eye in the control group), and HRT with 
low reliability (one eye in the GA group and two eyes in the 
control group). The exclusions were limited to the period 
during which the event occurred (for each patient, if one 
or more examinations were excluded due to quality, future 
examinations from the same patient could enter in the 
analyses, if the quality was appropriate.) Table 2 shows the 
comparison between both groups regarding all anatomical 
and functional evaluation data.
Within group analysis
A statistically significant difference in RNFL thickness was 
detected in the inferior peripapillary region and in the   average 
thickness measurements assessed by OCT in the control group 
when comparing preoperative values to those obtained at 
12 month follow-up. The control group had an initial mean 
(±SE) inferior RNFL thickness of 143.98 µm ± 4.62 µm and an 
average thickness of 119.84 µm ± 5.82 µm, and these became 
significantly thinner at 1 year post-PRP: 132.01 µm ± 6.30 µm 
and 110.07 µm ± 5.09 µm, respectively.
Between group analysis
Figure 2 shows less RNFL atrophy, less visual field mean 
deviation (VFMD) worsening and less B-wave reduction in 
the GA group although these differences were not statistically 
significant. The mean logMAR BCVA in the group treated 
with GA was 0.362 compared with 0.598 in the placebo group 
at 6 months. The difference reached significance, but it was 
not sustained when the analysis was performed with macular 
thickness as a covariable (Table 2). Macular thickness was 
significantly different between groups; it was higher in the 
control group in all examinations. We found no statistically 
significant difference between groups regarding HRT or FDT 
(data not shown).
No drug-related adverse events were observed in any 
patients treated with GA or placebo.
Discussion
Laser photocoagulation, which is the common treatment 
of choice for diabetes, has a negative impact on retinal 
  ganglion cell survival, leading to the significant progression 
of morphological and functional damage.6–8 Rescue of such 
retinal ganglion cells could be achieved, in principle, by 
neuroprotection.9,10,14 Here we present a pilot study disclosing 
a potential beneficial effect of neuroprotective vaccination 
in these patients.
Neuroprotective immunization is based on the concept 
of “protective autoimmunity” formulated by Schwartz’s 
group,20 who showed that a T cell-mediated immune response 
is   neuroprotective after injury and that its effect can be 
boosted by either passive or active immunization.11,12,21,22 
It has been demonstrated that adoptive transfer of T cells 
specific for proteins associated with CNS myelin, such as 
myelin basic protein, reduces the post-traumatic secondary 
degeneration of the rat optic nerve and spinal cord.20 It was 
found that T cells, upon recognizing their antigen, secrete 
growth factors and facilitate recruitment of blood monocytes 
that locally display a regulatory role that helps restore homeo-
stasis in nervous system maintenance.23,24 Immune response 
boosting can be achieved by immunization with peptides 
derived from relevant autoantigens, or by synthetic antigens, 
such as GA, that weakly cross-react with self-antigens.12 
Such neuroprotection increases the ability of the damaged 
tissue to cope with the neurotoxicity and thereby to arrest 
the spread of laser damage.
Belokopytov et al used electroretinography to demonstrate 
the neuroprotective effect of GA treatment for retinal laser 
burns in rats.25 This was the first report of   neuroprotection 
of nonmyelinated neurons. A similar laser injury model was Clinical Ophthalmology 2011:5
Table 2 evaluation of mean differences for anatomical and functional parameters (between and within comparisons considered, 
adjusted for repeated measurements)
Parameter Period GA group (n = 13) Control group (n = 13) Mean difference (CI 95%)
Functional parameters
BCVA (logMAr) Pre 0.398 (0.077) 0.493 (0.065) 0.095 (−0.103; 0.293)
6 months 0.362 (0.073) 0.598 (0.093) 0.236 (0.005; 0.467)
1 year 0.386 (0.089) 0.641 (0.118) 0.255 (−0.035; 0.545)
BCVA (logMAr) Pre 0.548 (0.075) 0.457 (0.071 ) −0.091 (−0.301; 0.119)
adjusted for OCT MT 6 months 0.415a (0.044) 0.433 (0.059) 0.019 (−0.132; 0.169)
1 year 0.419 (0.054) 0.483 (0.072) 0.064 (−0.116; 0.245)
VF_MD Pre −6.29 (0.39) −6.58 (0.73) −0.29 (−1.92; 1.33)
1 month −7.21a (0.54) −8.75a (0.81) −1.54 (−3.45; 0.37)
3 months −7.10 (0.66) −8.83a (1.17) −1.73 (−4.36; 0.90)
6 months −7.88a (0.56) −8.96a (1.16) −1.08 (−3.60; 1.45)
1 year −8.70a (1.08) −10.06a,b (1.46) −1.36 (−4.97; 2.20)
erg_b Pre 347.66 (30.33) 340.81 (26.64) −6.85 (−85.95; 72.26)
6 months 244.32a (19.42) 205.65a (24.22) −38.67 (99.50; 22.17)
erg_b/a Pre 3.01 (0.30) 2.90 (0.28) −0.12 (−0.93; 0.70)
6 months 3.16 (0.27) 2.96 (0.22) −0.20 (−0.89; 0.49)
erg_OP Pre 78.65 (9.81) 55.58 (10.28) −23.07 (−50.92; 4.78)
6 months 42.24a (7.65) 29.79a (4.94) −12.44 (−30.29; 5.41)
Anatomic parameters
OCT_sUP Pre 142.35 (8.66) 139.04 (8.94) −3.31 (−27.71; 21.09)
1 month 142.22 (8.35) 139.27 (6.40) −2.95 (−23.58; 17.67)
3 months 136.78 (5.78) 140.39 (7.07) 3.61 (−14.30; 21.51)
6 months 135.33 (5.85) 134.33 (6.94) −0.99 (−18.78; 16.79)
1 year 140.90 (14.59) 130.56 (5.83) −10.35 (−41.14; 20.45)
OCT_inF Pre 142.44 (4.78) 143.98 (4.62) 1.54 (−11.49; 14.57)
1 month 145.44 (4.89) 141.86 (6.08) −3.58 (18.86; 11.71)
3 months 144.65 (5.48) 139.66 (5.01) −5.00 (−19.55; 9.55)
6 months 146.13 (5.58) 140.21 (5.19) −5.92 (−20.85; 9.02)
1 year 142.28 (7.74) 132.01a,b (6.30) −10.27 (−29.82; 9.28)
OCT_AVT Pre 114.97 (5.35) 119.84 (5.82) 4.87 (−10.63; 20.38)
1 month 118.09 (5.07) 117.97 (4.80) −0.11 (−13.80; 13.57)
3 months 115.79 (4.46) 117.01 (5.15) 1.22 (−12.13; 14.58)
6 months 115.11 (5.05) 114.09 (5.12) −1.02 (−15.11; 13.07)
1 year 112.98 (7.80) 110.07a (5.09) −2.90 (−21.16; 15.35)
OCT_MT Pre 227.85 (21.17) 358.68 (19.27) 130.83 (74.73; 186.93)
1 month 280.26a (35.03) 387.26 (33.66) 106.41 (11.20; 201.63)
3 months 272.63a (29.87) 384.69 (36.69) 112.06 (19.33; 204.79)
6 months 294.08a (29.13) 391.32 (32.34) 97.24 (11.93; 182.55)
1 year 306.88a (27.24) 390.98 (32.28) 84.11 (1.31; 166.90)
Notes: statistical comparisons within group: aP , 0.05 when compared with pretreatment; bP , 0.05 when compared with 6 months; data presented as means (standard errors).
Abbreviations: GA group, treated with glatiramer acetate; BCVA, best corrected visual acuity; CI, confidence interval; VF_MD, visual field _ mean deviation; OCT_SUP, 
OCT_inF, OCT_AVT, OCT_MT: optical coherence tomography superior, inferior, average thickness, macular thickness; erg_b, erg_b/a, erg_OP: electroretinography   
b wave, b/a wave, oscillatory potential.
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used by Shulman et al to study   neuroprotection with PN-277, 
another synthetic peptide capable of boosting the immune 
system and enhancing neurotrophic factor secretion.26 Both 
drugs demonstrated an ameliorative effect in neural tissue 
such as the retina. In humans, Landa et al found that GA 
reduced the drusen area in dry age-related macular disease.27 
The main protein present in drusen is beta-amyloid, which 
is also present in   Alzheimer’s disease (AD) plaques. Recent 
evidence showed that T   cell-based   vaccination with GA in 
AD mice model resulted in   modulation of microglia into a 
neuroprotective phenotype. As a result, reduction of cognitive 
decline, elimination of plaque formation, and induction of 
neuronal survival and neurogenesis was observed.15 This type 
of immunization may be of clinical significance in reducing 
laser-induced retinal injuries in humans.
In our study, the comparison between pre- and post-
PRP in the same group showed a statistically significant 
worsening in the placebo group, as demonstrated by 
thinning of inferior RFNL and average thickness (measured 
by OCT), which did not occur in the group treated Clinical Ophthalmology 2011:5
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Figure 2 Functional and anatomical examinations at baseline and follow-up.
Note: Data are presented as means ± standard error of the mean.
Abbreviations: gA group, treated with glatiramer acetate; (A) VF_MD, visual 
field mean deviation; (B) OCT_inF, inferior retinal thickness in optical coherence 
tomography; (C) erg_B, electroretinography B wave.
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with glatiramer acetate. Lim et al found thinner RNFL 
measurements in the inferior and nasal peripapillary regions 
in diabetic patients with PRP compared with both diabetic 
patients without PRP and normal eyes.17 Kim and Cho also 
observed reduction in RNFL (average thickness) 6 months 
post-PRP in the analysis within groups.28 Finally, Muqit 
et al initially found increased thickness in the group treated 
10 weeks post-laser, and thickness reduction 6 months after 
treatment.29
Our data also revealed less NFL atrophy, less VFMD 
worsening and less B-wave reduction in the treatment group 
as compared with the controls, but the difference was not 
significant, possibly because of the wide variability in 
the sample and follow-up problems that led to a smaller 
sample and loss of test power. Visual acuity was better in 
the GA group at 6 months after treatment, but the difference 
was not sustained when the analysis was performed with 
macular thickness as a covariable. Macular thickness was 
significantly different between groups; macular thickness 
was higher in the control group in all examinations.
Importantly, GA was given weekly in this study; in 
contrast to its daily administration in patients suffering 
from relapsing-remitting multiple sclerosis.14 The daily 
administration of GA in an animal model of glaucoma was 
ineffective.13
Our study was limited to 47 eyes, largely because 
the number of patients with severe nonproliferative dia-
betic retinopathy or proliferative diabetic retinopathy 
with no   previous treatment and good vision was limited. 
Another limitation was the worsening of diabetic retin-
opathy   throughout the study due to inappropriate systemic 
  control.30 In the present study, we had some complications, 
such as the worsening of macular edema, tractional retinal 
  detachment, vitreous   hemorrhage and others, that impaired 
the   comparative   anatomical and functional evaluation for 
some patients. Despite the limitations described above, 
the current study was conducted using rigorous scientific 
  methodology and provides encouraging pilot data that justify 
a large, multicenter, randomized clinical trial to confirm the 
efficacy of GA.
Conclusion
The results of this study suggest that weekly GA treatment 
has a potential neuroprotective effect on the RNFL following 
photocoagulation for diabetic retinopathy.
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